Lantus revelations
September 21, 2010
PATIENT-level data from a recent
randomised clinical trial undertaken
by Sanofi-Aventis has revealed that
adding Lantus(R) (insulin glargine
[rDNA] injection) to patients with
type 2 diabetes, uncontrolled on
oral antidiabetic drug therapy
(OADs), created a greater
reduction in A1C levels and a
lower incidence of hypoglycemia
compared to all comparators
(OADs, NPH, lispro, premix).
Presented at the European
Association for the Study of
Diabetes’ 46th Annual Meeting in
Stockholm, the results were
backed up with a pooled analysis
of several clinical studies which
also found that when type 2
diabetes sufferers used Lantus (R)
as either a monotherapy, or in
conjunction with an antidiabetic
agent, a greater reduction in A1C
was noted, as also was a lower risk
of hypoglycemia compared to
patients taking two OADs.
MEANWHILE Sanofi-Aventus
also revealed this week the results
of its Phase III clinical trial
program assessing the efficacy and
safety of lixisenatide, the
company’s new once-daily GLP-1
receptor agonist, as monotherapy
in patients with type 2 diabetes.
Results from the trial found that
as a once-daily GLP-1 agent,
lixisenatide substantially reduced
A1C and had a “pronounced effect
on post meal glucose control”.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Sep 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Sep 10
